XOMA (NASDAQ:XOMA) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other equities research analysts have also weighed in on the stock. S&P Equity Research decreased their price objective on shares of XOMA from $18.74 to $16.26 in a report on Tuesday, August 14th. Zacks Investment Research lowered shares of XOMA from a “hold” rating to a “sell” rating in a report on Saturday, August 11th. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of XOMA in a report on Wednesday, August 8th. TheStreet upgraded shares of XOMA from a “d” rating to a “c-” rating in a report on Tuesday, June 12th. Finally, Cowen reiterated a “hold” rating on shares of XOMA in a report on Thursday, May 10th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $31.32.

Shares of XOMA opened at $17.60 on Friday. XOMA has a 1-year low of $15.35 and a 1-year high of $37.25. The stock has a market cap of $143.09 million, a P/E ratio of 17.96 and a beta of 2.46. The company has a debt-to-equity ratio of 3.06, a current ratio of 12.46 and a quick ratio of 12.46.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). XOMA had a net margin of 43.55% and a return on equity of 379.39%. The company had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.57 million. research analysts forecast that XOMA will post -0.89 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new stake in shares of XOMA in the 1st quarter valued at about $243,000. Allianz Asset Management GmbH raised its holdings in shares of XOMA by 32.7% in the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 3,020 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in shares of XOMA in the 1st quarter valued at about $283,000. ClariVest Asset Management LLC bought a new stake in shares of XOMA in the 1st quarter valued at about $380,000. Finally, Dynamic Technology Lab Private Ltd raised its holdings in shares of XOMA by 57.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 7,349 shares in the last quarter. Institutional investors and hedge funds own 43.60% of the company’s stock.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Featured Article: Understanding Average Daily Trade Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.